Description

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.

Faculty

  • Aleksander Krag (Moderator)
  • Aftab Ala (Faculty)
  • Pavel Strnad (Faculty)
  • Alice Turner (Faculty)

Related episodes

This episode is scheduled in honour of the Rare Disease Day (29 February).

ℹ️ Please click here to watch this EASL Studio episode.

Listen to the podcast

 

This podcast is also available on the following platforms:

spotify      Amazon music      Apple

Log in to post comments
EASL Membership
Off